WASHINGTON (dpa-AFX) - Thursday, AbbVie Inc. (ABBV) reported positive
results from the Phase 3b/4 LEVEL UP study comparing the effectiveness and
safety of its drug, Upadacitinib/Rinvoq, with Regeneron Pharmaceuticals and
Sanofi's drug, Dupilumab/Dupixent, for moderate-to-severe atopic dermatitis in
adults and adolescents.

The study showed that Rinvoq demonstrated better efficacy than Dupixent in
achieving the primary endpoint of a 90% or greater reduction in EASI 90 and
WP-NRS of 0/1 at week 16. Additionally, Rinvoq outperformed Dupixent in all
secondary endpoints, including rapid near-complete skin clearance and reduced
itch.

The company plans to present the LEVEL UP study results at an upcoming medical
congress.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX